| 摘要 |
Inflammation in particular contact dermatitis, rheumatoid arthritis and allograft rejection caused by overproduction of nitric oxide in immune cells is prevented or treated with at least one tetrahydrobiopterin synthesis antagonist. The antagonist can be a guanosine triphosphate pathway tetrahydrobiopterin synthesis antagonist and/or a pterin salvage pathway tetrahydrobiopterin synthesis antagonists. Selected from oxidized pterins and reduced pterins, substituted pyrimidines, N-acetylserotonin, N-acetyldopamine, N-acetyl-m-tyramine, N-chloroacetyldopamine, N-chloroacetylserotonin, N-methoxyacetyldopamine and N-methoxyacetylserotonin. Unwanted counterproductive or side effects can be eliminated or ameliorated by administration additionally of levodopa with or without carbidopa and of L-5-hydroxytrytophane.
|
